Revolution Medicines Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 103.69, 672.32, 1492.79, 2493.18, 4562.19 ], "ebit_estimate": [ -1681.58, -1268.14, -473.41, 890.69, 2488.53 ], "ebitda_estimate": [ -1716.84, -1519.69, -1175.24, -830.39, 2134.53 ], "net_income_estimate": [ -1636.99, -1228.61, -731.39, 644.93, 2349.37 ], "per_share_eps_estimate": [ -8, -6.06, -2.41, 3.41, 10.54 ], "eps_nri_estimate": [ -7.98, -5.8, -2.33, 4.11, 10.52 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 10.16, 2.25, 4.52, null, null ], "pretax_income_estimate": [ -1641.08, -1224.91, -595.54, 826.05, 2599.59 ], "operating_cash_flow_per_share_estimate": [ -6.82, -6.16, -4.89, null, null ], "roa_estimate": [ -65.55, -65.8, -84.3, null, null ], "roe_estimate": [ -87.27, -80.74, -175.09, null, null ], "gross_margin_estimate": [ 95.21, 87.4, 90, 91.28, 92.74 ], "operating_cash_flow_estimate": [ -1351.03, -1219.63, -968.7, null, null ], "pettm_estimate": [ 0, 0, 0, 54.76, 17.73 ], "long_term_growth_rate_mean": 26.85, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": 25.87, "future_eps_nri_estimate_growth": 26.85, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": 26.13, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": 19.89, "future_book_value_per_share_estimate_growth": -28.31, "future_roa_estimate_growth": -19.93, "future_roe_estimate_growth": -38.17, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712", "202803" ], "revenue_estimate": [ 18.06, 8.19, 70.51, 83.18, 121.32, 191.57, 287.3, 150 ], "ebit_estimate": [ -422.46, -436.26, -385, -384.2, -345.51, -303.71, -274.2, -374.05 ], "ebitda_estimate": [ -450.28, -452.4, -371.01, -257.05, -213.37, -161.99, -122.8, -372.36 ], "net_income_estimate": [ -410.61, -417.3, -377.28, -367.67, -331.14, -293.13, -262.62, -350.82 ], "per_share_eps_estimate": [ -1.97, -2, -1.76, -1.45, -1.45, -1.24, -0.83, -1.63 ], "eps_nri_estimate": [ -1.96, -1.99, -1.74, -1.41, -1.38, -1.15, -0.95, -1.63 ], "dividend_estimate": [ null, null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null, null ], "pretax_income_estimate": [ -409.77, -416.52, -380.59, -367.67, -331.14, -293.13, -262.62, -350.82 ], "operating_cash_flow_per_share_estimate": [ -1.97, -1.88, -1.8, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null, null ], "gross_margin_estimate": [ null, 93, 92.67, 84, 84, 84, 84, 80 ], "operating_cash_flow_estimate": [ -390.25, -372.42, -356.58, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": 26.85, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": 25.87, "future_eps_nri_estimate_growth": 26.85, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": 26.13, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": 19.89, "future_book_value_per_share_estimate_growth": -28.31, "future_roa_estimate_growth": -19.93, "future_roe_estimate_growth": -38.17, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }